ArticleJournal of clinical microbiology2016
Identification and Antifungal Susceptibility Profile of Candida guilliermondii and Candida fermentati from a Multicenter Study in China.
Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Global Epidemiology of Invasive Infections by UncommonJournal of fungi (Basel, Switzerland) · 2024Review
- Emergence of cryptic species and clades ofMicrobiology spectrum · 2023Article
- Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009-2020.Medical mycology · 2023Article
- Article
- How to Identify Invasive Candidemia in ICU-A Narrative Review.Antibiotics (Basel, Switzerland) · 2022Review
- Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Distribution and antifungal susceptibility pattern ofVirulence · 2022Review
- The Antimicrobial Peptide AMP-17 Derived fromAntibiotics (Basel, Switzerland) · 2022Article
- Diagnosis and Treatment of Invasive Candidiasis.Antibiotics (Basel, Switzerland) · 2022Review
- Detection and Molecular Identification of EightMicroorganisms · 2022Article
- The Flo Adhesin Family.Pathogens (Basel, Switzerland) · 2021Review
- Clinical Characteristics and Outcomes of Candidemia Caused by Meyerozyma guilliermondii Complex in Cancer Patients Undergoing Surgery.Mycopathologia · 2020Article
- Five-Year National Surveillance of Invasive Candidiasis: Species Distribution and Azole Susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study.Journal of clinical microbiology · 2018Article
- Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.Antimicrobial agents and chemotherapy · 2018Article
- Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.Antimicrobial agents and chemotherapy · 2017Article
- Molecular epidemiology and azole resistance mechanism study of Candida guilliermondii from a Chinese surveillance system.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With molecular sequencing as a gold standard, the Vitek MS, Bruker Biotyper MS, and Vitek-2 Compact systems correctly identified 92.7%, 97.0%, and 15.2% of 164 Candida guillermondii isolates, respectively, and none of 8 C. fermentati isolates. All of the isolates showed high susceptibility to echinocandins, but some C. guilliermondii isolates showed low azole susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.